BioCentury | Jun 13, 2016
Company News

Mayo Clinic, TapImmune deal

...deal with Mayo to license exclusive, worldwide rights to develop and commercialize Mayo’s HER2/neu peptide vaccine ( TPIV100...
...costs. TapImmune plans to begin a Phase II trial at the start of next year. TPIV100...
BioCentury | Jul 13, 2015
Clinical News

HER2/neu peptide vaccine: Additional Phase I data

...II/III breast cancer in an open-label, U.S. Phase I trial showed that 6 injections of TPIV100...
...Mayo Clinic (see BioCentury, June 7, 2010). Mayo Clinic , Rochester, Minn. Product: HER2/neu peptide vaccine ( TPIV100...
BioCentury | Mar 31, 2014
Company News

TapImmune, Mayo Clinic deal

...Mayo could not be reached. Mayo is also conducting a Phase I trial evaluating an HER2/neu peptide vaccine...
BioCentury | Mar 10, 2014
Clinical News

HER2/neu peptide vaccine: Interim Phase I data

...the first set of 6 patients in an open-label Phase I trial showed that intradermal HER2/neu peptide vaccine...
...Herceptin in the U.S., while Roche markets it elsewhere. Mayo Clinic , Rochester, Minn. Product: HER2/neu peptide vaccine...
BioCentury | Jan 14, 2013
Clinical News

HER2/neu peptide vaccine: Phase I ongoing

...TapImmune Inc. (OTCBB:TPIV, Seattle, Wash.) said an open-label Phase I trial of intradermal HER2/neu peptide vaccine will continue...
...Herceptin in the U.S., while Roche markets it elsewhere. Mayo Clinic , Rochester, Minn. Product: HER2/neu peptide vaccine...
BioCentury | Oct 23, 2000
Strategy

Growing a pipeline

...II Rheumatoid arthritis AnergiX.RA vaccine Phase II Rheumatoid arthritis AnergiX.MS vaccine Phase II Multiple sclerosis Her2/neu peptide vaccine...
BioCentury | Mar 22, 1999
Clinical News

Corixa regulatory update

The University of Washington (Seattle, Wash.) received U.S. Patent No. 5,876,712 covering the use of autologous T cells stimulated with the Her-2/neu protein ex vivo to treat patients with cancers expressing Her-2/neu. CRXA is the...
BioCentury | May 26, 1998
Tools & Techniques

Ideas from ASCO

About 30 percent of breast cancers and some other cancers overexpress the HER-2 growth factor receptor. The marker is associated with aggressive disease, rapid progression and shortened survival. Therapies targeted at HER-2 are beginning to...
BioCentury | May 26, 1998
Clinical News

Her-2/neu peptide vaccine: Phase I

CRXA said that an immune response was induced to the protein in 16 of 22 patients who completed treatment with its Her-2/neu vaccine . Efficacy was not evaluated. Toxicities were hives and muscle aches. To date,...
BioCentury | Apr 27, 1998
Tools & Techniques

An immunotherapeutic pipeline

An immunotherapeutic pipeline Company Product Description Cancer type Status AltaRex Ovarex Anti-ideotype vaccine Ovarian IIb Antigenics HSPPC-96 Autologous heat-shock vaccine Pancreatic, melanoma, renal cell carcinoma Ib Aphton Gastrimmune Gastrin-17 antigen Gastrointestinal III Avax M-Vax Autologous...
Items per page:
1 - 10 of 10